ARTICLE | Clinical News
Seebri Breezhaler regulatory update
October 1, 2012 7:00 AM UTC
Japan's Ministry of Health, Labor and Welfare (MHLW) approved Seebri glycopyrronium bromide Inhalation Capsules (NVA237) from Novartis as a once-daily inhaled maintenance bronchodilator treatment for chronic obstructive pulmonary disease (COPD). The product will be available in Japan by year end. Novartis has global rights to Seebri from Vectura Sosei, which will each receive a $2.5 million payment triggered by the approval. ...